Rheumatoid Arthritis
Conditions
Keywords
moderate Rheumatoid Arthritis, severe Rheumatoid Arthritis, subcutaneous, Olokizumab
Brief summary
The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving, but not fully responding to treatment with methotrexate (MTX). The primary objective of this study was to evaluate the efficacy of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) relative to placebo in subjects with moderately to severely active rheumatoid arthritis (RA) inadequately controlled by methotrexate (MTX) therapy.
Detailed description
The goal of this Phase III study was to assess the efficacy, tolerability, and safety of OKZ in subjects with moderately to severely active RA who had responded inadequately to MTX. The primary endpoint of the trial was at Week 12. Olokizumab was expected to reduce the disease activity and improve physical function. The study was expected to provide safety information in a large group of subjects over at least a 24 week period. The CREDO 1 study included a 4-week Screening Period, a double-blind Treatment Period from Week 0 to Week 24, and a Safety Follow-Up Period from Week 24 to Week 44. At randomization, a total of 428 eligible subjects were randomly assigned to 1 of 3 treatment groups in a 1:1:1 ratio: 1. OKZ 64 mg q4w: SC injection of OKZ 64 mg q4w (alternating with SC injection of placebo OKZ q4w to maintain blinding) + MTX. 2. OKZ 64 mg q2w: SC injection of OKZ 64 mg q2w + MTX. 3. Placebo: SC injection of placebo q2w + MTX Throughout the double-blind Treatment Period, all subjects were required to remain on a stable dose of background MTX at 15 to 25 mg/week (or ≥ 10 mg/week if there was documented intolerance to higher doses) with a stable route of administration, and concomitant treatment with folic acid ≥5 mg per week or equivalent is required for all subjects. The last dose of study treatment (OKZ or placebo) was at Week 22 in all groups. Following Visit 2 (randomization), subjects returned to the study site at least every other week through Week 24 for response and safety assessments as per the study Schedule of Events. Subjects were classified in terms of their response to study treatment at Week 14, with non-responders defined as subjects in any treatment group who had not improved by at least 20% in both swollen and tender joint counts (66-68 joint assessment). Starting at or as close as possible to Week 14, non-responders were administered sulfasalazine and/or hydroxychloroquine as rescue medication in addition to the assigned treatment. After completion of the 24-week double-blind Treatment Period, subjects either rolled over into the long-term open-label extension (OLE) study or entered the Safety Follow-Up Period. During the Safety Follow-Up Period, subjects returned for visits +4, +8, and +22 weeks after the last dose of study treatment. Subjects who discontinued the randomized treatment prematurely were required to come for the End of Treatment (EoT) Visit 2 weeks after the last study treatment administration and then continued with the scheduled study visits as per the Schedule of Events. The study was conducted at approximately 50 sites across 4 countries globally, which included Russia, Belarus, Turkey, and Bulgaria.
Interventions
DRUGOlokizumab
160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
DRUGPlacebo
sodium chloride 0.9% solution supplied in polypropylene plastic ampoules of 10 mL cartons to contain 10 ampoules
Sponsors
Quintiles, Inc.
OCT Clinical Trials
Mene Research
R-Pharm International, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Subjects may be enrolled in the study only if they meet all of the following criteria: * Subjects willing and able to sign informed consent * Subjects must have a diagnosis of adult onset RA classified by ACR/EULAR 2010 revised classification criteria for RA for at least 12 weeks prior to Screening. * Inadequate response to treatment with MTX for at least 12 weeks prior to Screening at a dose of 15 to 25 mg/week (or ≥10 mg/week if intolerant to higher doses). * The dose and means of administering MTX must have been stable for at least 6 weeks prior to Screening. * Subjects must be willing to take folic acid or equivalent throughout the study * Subjects must have moderately to severely active RA disease as defined by all of the following: * ≥6 tender joints (68 joint count) at Screening and baseline; and * ≥6 swollen joints (66 joint count) at Screening and baseline; and * CRP above ULN at Screening based on the central laboratory results.
Exclusion criteria
* Diagnosis of any other inflammatory arthritis or systemic rheumatic disease (e.g., gout, psoriatic or reactive arthritis, Crohn's disease, Lyme disease, juvenile idiopathic arthritis, or systemic lupus erythematosus). However, subjects could have secondary Sjogren's syndrome or hypothyroidism * Subjects who were Steinbrocker class IV functional capacity (incapacitated, largely or wholly bed-ridden or confined to a wheelchair, with little or no self-care) * Prior exposure to any licensed or investigational compound directly or indirectly targeting IL-6 or IL-6R (including tofacitinib or other Janus kinases and spleen tyrosine kinase \[SYK\] inhibitors) * Prior treatment with cell-depleting therapies, including anti-CD20 or investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3, and anti-CD19) * Prior use of bDMARDs, with the following exception: • Subjects who discontinued TNFi therapy due to a reason other than lack of efficacy were allowed to enter the study (TNFi therapy was not to be discontinued to facilitate a subject's participation in the study but should instead have been previously discontinued as part of a subject's medical management of RA). The use of TNFi therapy within the following windows prior to baseline was exclusionary: 1. 4 weeks for etanercept 2. 8 weeks for infliximab 3. 10 weeks for adalimumab, certolizumab, and golimumab * Use of parenteral and/or intra-articular glucocorticoids within 4 weeks prior to baseline * Use of oral glucocorticoids greater than 10 mg/day prednisone (or equivalent), or change in dosage within 2 weeks prior to baseline * Prior documented history of no response to hydroxychloroquine and sulfasalazine * Prior use of cDMARDs (other than MTX) within the following windows prior to baseline (cDMARDs were not to be discontinued to facilitate a subject's participation in the study, but should instead have been previously discontinued as part of a subject's medical management of RA): 1. 4 weeks for sulfasalazine, azathioprine, cyclosporine, hydroxychloroquine, chloroquine, gold, penicillamine, minocycline, or doxycycline 2. 12 weeks for leflunomide unless the subject has completed the following elimination procedure at least 4 weeks prior to baseline: Cholestyramine at a dosage of 8 grams 3 times daily for at least 24 hours, or activated charcoal at a dosage of 50 grams 4 times daily for at least 24 hours 3. 24 weeks for cyclophosphamide * Vaccination with live vaccines in the 6 weeks prior to baseline or planned vaccination with live vaccines during the study * Participation in any other investigational drug study within 30 days or 5 times the terminal half-life of the investigational drug, whichever is longer, prior to baseline * Other treatments for RA (e.g., Prosorba Device/Column) within 6 months prior to baseline * Use of intra-articular hyaluronic acid injections within 4 weeks prior to baseline * Use of non-steroidal anti-inflammatory drugs (NSAIDs) on unstable dose or switching of NSAIDs within 2 weeks prior to baseline * Previous participation in this study (randomized) or another study of OKZ * Subjects with acute or chronic viral hepatitis B or C infection as detected by blood tests at Screening (e.g., positive for hepatitis B surface antigen \[HBsAg\], total hepatitis B core antibody \[anti-HBc\], or hepatitis C virus antibody \[HCV Ab\]) a. Subjects who were positive for hepatitis B surface antibody (anti-HBs), but negative for HBsAg and anti-HBc, were eligible * Subjects with HIV infection * Subjects with: 1. Suspected or confirmed current active TB disease or a history of active TB disease 2. Close contact (i.e., sharing the same household or other enclosed environment, such as a social gathering place, workplace, or facility, for extended periods during the day) with an individual with active TB within 1.5 years prior to Screening. * Concurrent malignancy or a history of malignancy within the last 5 years (with the exception of successfully treated carcinoma in situ of the cervix and successfully treated basal cell carcinoma and squamous cell carcinoma not less than 1 year prior to Screening \[and no more than 3 excised skin cancers within the last 5 years prior to Screening\]) * Subjects with any infection requiring oral antibiotic or antiviral therapy in the 2 weeks prior to Screening or at baseline, injectable anti-infective therapy in the last 4 weeks prior to baseline, or serious or recurrent infection with a history of hospitalization in the 6 months prior to baseline * Subjects with evidence of disseminated herpes zoster infection, zoster encephalitis, meningitis, or other non-self-limited herpes zoster infections in the 6 months prior to baseline * Subjects with planned surgery during the study or surgery ≤4 weeks prior to Screening and from which the subject had not fully recovered, as judged by the Investigator * Subjects with diverticulitis or other symptomatic GI conditions that might predispose the subject to perforations, including subjects with a history of such predisposing conditions (e.g., diverticulitis, GI perforation, or ulcerative colitis) * Pre-existing central nervous system demyelinating disorders (e.g., multiple sclerosis and optic neuritis) * History of chronic alcohol or drug abuse as judged by the Investigator * Female subjects who are pregnant, currently lactating, have lactated within the last 12 weeks, or who were planning to become pregnant during the study or within 6 months of last dose of study treatment * Female subjects of childbearing potential (unless permanent cessation of menstrual periods, determined retrospectively after a woman had experienced 12 months of natural amenorrhea as defined by the amenorrhea with underlying status \[e.g., correlative age\] or 6 months of natural amenorrhea with documented serum follicle-stimulating hormone levels \>40 mIU/mL and estradiol \<20 pg/mL) who were not willing to use a highly effective method of contraception during the study and for at least 6 months after the last administration of study treatment OR Male subjects with partners of childbearing potential not willing to use a highly effective method of contraception during the study and for at least 3 months after the last administration of study treatment; * Subjects with a known hypersensitivity to any component of the OKZ drug product, or placebo * Subjects with a known hypersensitivity or contraindication to any component of the rescue medication * History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response | at Week 12 | A responder was defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12. The calculations were based on a ≥ 20% improvement from baseline in the swollen joint count (SJC) assessed in 66 joints and in the tender joint count (TJC) assessed in 68 joints; and a ≥ 20% improvement from baseline in at least 3 of the 5 remaining core set measures: Patient Global Assessment of Disease Activity (Visual Analog Scale (VAS) assessment), Patient Assessment of Pain (VAS assessment), Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician Global Assessment (VAS assessment), Level of acute phase reactant (CRP or ESR, using level of CRP in this study). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Subjects Achieving Low Disease Activity | at Week 12 | Defined as Disease Activity Score 28 (DAS28) (CRP) \< 3.2, and remaining on randomized treatment and in the study at Week 12. |
| Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) | Baseline to Week 12 | Change of physical ability from baseline (the last available assessment prior to the first dose of the study treatment) to week 12, as measured by HAQ-DI. The HAQ-DI total score ranges from 0 (the best outcome) to 3 (the worst outcome).The HAQ-DI assesses the degree of difficulty experienced in 8 domains (dressing and grooming, arising, eating, walking, hygiene, reach, grip, common daily activities) of daily living activities using 20 questions. Each domain consists of 2 or 3 items. For each question the level of difficulty is scored from 0 (without any difficulty, the best outcome) to 3 (unable to do, the worst outcome). Each category is given a score by taking the maximum score of each question. The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered. If fewer than 6 categories had responses, no disability score was calculated. |
| Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response | at Week 24 | A responder was defined as any subject satisfying ACR50 criteria and remaining on randomized treatment and in the study at Week 24. The calculations were based on a ≥ 50% improvement from baseline in the swollen joint count (SJC) assessed in 66 joints and in the tender joint count (TJC) assessed in 68 joints; and a ≥ 50% improvement from baseline in at least 3 of the 5 remaining core set measures: Patient Global Assessment of Disease Activity (Visual Analog Scale (VAS) assessment), Patient Assessment of Pain (VAS assessment), Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician Global Assessment (VAS assessment), Level of acute phase reactant (CRP or ESR, using level of CRP in this study). |
| Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission) | at Week 24 | Percentage of subjects with Clinical Disease Activity Index (CDAI) ≤ 2.8 (remission) and remaining on randomized treatment and in the study at Week 24 |
Countries
Belarus, Bulgaria, Russia
Participant flow
Recruitment details
Enrollment was conducted at 42 clinical sites (in Belarus, Bulgaria, Russia,Turkey) between May 2016 and April 2018. 785 patients were included, 357 patients screen-failed, 428 patients were randomized (143 patients in OKZ q2w +MTX group, 142 patients in OKZ q4w +MTX group, 143 patients in Placebo q2w +MTX group). 1 subject was randomized by mistake and didn't receive the study treatment. The primary efficacy analysis set included 428 subjects, and the safety analysis set included 427 subjects.
Participants by arm
| Arm | Count |
|---|---|
| Arm 1: Olokizumab q4w + Methotrexate Olokizumab 64 mg Subcutaneous q4w +placebo q4w+ Methotrexate (oral)
Olokizumab q4w: 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial + placebo (sodium chloride 0.9% solution supplied in polypropylene plastic ampoules of 10 mL cartons to contain 10 ampoules) | 142 |
| Arm 2: Olokizumab q2w + Methotrexate Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)
Olokizumab q2w: 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial | 143 |
| Arm 3: Placebo q2w + Methotrexate Placebo Subcutaneous q2w + Methotrexate (oral)
Placebo q2w: sodium chloride 0.9% solution supplied in polypropylene plastic ampoules of 10 mL cartons to contain 10 ampoules | 143 |
| Total | 428 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Death | 0 | 1 | 0 |
| Overall Study | Screen Failure | 0 | 0 | 1 |
| Overall Study | Withdrawal by Sponsor | 0 | 0 | 1 |
| Overall Study | Withdrawal by Subject | 8 | 12 | 9 |
Baseline characteristics
| Characteristic | Arm 1: Olokizumab q4w + Methotrexate | Arm 2: Olokizumab q2w + Methotrexate | Arm 3: Placebo q2w + Methotrexate | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 13 Participants | 18 Participants | 19 Participants | 50 Participants |
| Age, Categorical Between 18 and 65 years | 129 Participants | 125 Participants | 124 Participants | 378 Participants |
| Age, Continuous | 49.1 years STANDARD_DEVIATION 12.07 | 52.0 years STANDARD_DEVIATION 11.77 | 52.7 years STANDARD_DEVIATION 11.29 | 51.3 years STANDARD_DEVIATION 11.79 |
| Baseline Disease Severity Inactive (DAS28 (CRP) ≤ 3.2) | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Baseline Disease Severity Moderately Active (DAS28 (CRP) > 3.2 to ≤ 5.1) | 21 Participants | 18 Participants | 22 Participants | 61 Participants |
| Baseline Disease Severity Very Active (DAS28 (CRP) > 5.1) | 121 Participants | 123 Participants | 119 Participants | 363 Participants |
| Body Mass Index (BMI) | 26.40 kg/m^2 | 26.62 kg/m^2 | 26.93 kg/m^2 | 26.65 kg/m^2 |
| Race/Ethnicity, Customized participants Asian | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized participants Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized participants Other/Mixed | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized participants White | 142 Participants | 143 Participants | 142 Participants | 427 Participants |
| Region of Enrollment Belarus | 7 participants | 7 participants | 6 participants | 20 participants |
| Region of Enrollment Bulgaria | 6 participants | 12 participants | 9 participants | 27 participants |
| Region of Enrollment Russia | 129 participants | 124 participants | 128 participants | 381 participants |
| Sex: Female, Male Female | 118 Participants | 116 Participants | 120 Participants | 354 Participants |
| Sex: Female, Male Male | 24 Participants | 27 Participants | 23 Participants | 74 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 142 | 1 / 143 | 0 / 142 |
| other Total, other adverse events | 53 / 142 | 51 / 143 | 35 / 142 |
| serious Total, serious adverse events | 8 / 142 | 8 / 143 | 4 / 142 |
Outcome results
Primary
Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response
A responder was defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12. The calculations were based on a ≥ 20% improvement from baseline in the swollen joint count (SJC) assessed in 66 joints and in the tender joint count (TJC) assessed in 68 joints; and a ≥ 20% improvement from baseline in at least 3 of the 5 remaining core set measures: Patient Global Assessment of Disease Activity (Visual Analog Scale (VAS) assessment), Patient Assessment of Pain (VAS assessment), Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician Global Assessment (VAS assessment), Level of acute phase reactant (CRP or ESR, using level of CRP in this study).
Time frame: at Week 12
Population: Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm 1: Olokizumab q4w + Methotrexate | Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response | 100 Participants |
| Arm 2: Olokizumab q2w + Methotrexate | Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response | 91 Participants |
| Arm 3: Placebo q2w + Methotrexate | Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response | 37 Participants |
Comparison: The OKZ ACR20 response rates for 64 q2w treatment group at Week 12 are expected to be at least 55%, resulting in an expected difference in ACR20 response rates of 30 percentage points between respective OKZ treatment group and placebo. Sample size yield 100% disjunctive power for testing the primary hypothesis.p-value: <0.000197.5% CI: [0.248, 0.489]Chi-squared
Comparison: The OKZ ACR20 response rates for 64 q4w treatment group at Week 12 are expected to be at least 50%, resulting in an expected difference in ACR20 response rates of 25 percentage points between respective OKZ treatment group and placebo. Sample size yield 100% disjunctive power for testing the primary hypothesis.p-value: <0.000197.5% CI: [0.318, 0.552]Chi-squared
Secondary
Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire Disability Index (HAQ-DI)
Change of physical ability from baseline (the last available assessment prior to the first dose of the study treatment) to week 12, as measured by HAQ-DI. The HAQ-DI total score ranges from 0 (the best outcome) to 3 (the worst outcome).The HAQ-DI assesses the degree of difficulty experienced in 8 domains (dressing and grooming, arising, eating, walking, hygiene, reach, grip, common daily activities) of daily living activities using 20 questions. Each domain consists of 2 or 3 items. For each question the level of difficulty is scored from 0 (without any difficulty, the best outcome) to 3 (unable to do, the worst outcome). Each category is given a score by taking the maximum score of each question. The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered. If fewer than 6 categories had responses, no disability score was calculated.
Time frame: Baseline to Week 12
Population: Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population. Subjects with a missing baseline are not included. Data after treatment discontinuation are Included, Data after discontinuing study are multiply Imputed based on the return to baseline assumption.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Arm 1: Olokizumab q4w + Methotrexate | Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) | -0.52 score on a scale | Standard Error 0.046 |
| Arm 2: Olokizumab q2w + Methotrexate | Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) | -0.55 score on a scale | Standard Error 0.047 |
| Arm 3: Placebo q2w + Methotrexate | Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) | -0.23 score on a scale | Standard Error 0.044 |
p-value: <0.000197.5% CI: [-0.47, -0.21]ANCOVA
p-value: <0.000197.5% CI: [-0.49, -0.23]ANCOVA
Secondary
Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response
A responder was defined as any subject satisfying ACR50 criteria and remaining on randomized treatment and in the study at Week 24. The calculations were based on a ≥ 50% improvement from baseline in the swollen joint count (SJC) assessed in 66 joints and in the tender joint count (TJC) assessed in 68 joints; and a ≥ 50% improvement from baseline in at least 3 of the 5 remaining core set measures: Patient Global Assessment of Disease Activity (Visual Analog Scale (VAS) assessment), Patient Assessment of Pain (VAS assessment), Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician Global Assessment (VAS assessment), Level of acute phase reactant (CRP or ESR, using level of CRP in this study).
Time frame: at Week 24
Population: Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm 1: Olokizumab q4w + Methotrexate | Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response | 69 Participants |
| Arm 2: Olokizumab q2w + Methotrexate | Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response | 61 Participants |
| Arm 3: Placebo q2w + Methotrexate | Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response | 11 Participants |
p-value: <0.000197.5% CI: [0.239, 0.45]Chi-squared
p-value: <0.000197.5% CI: [0.296, 0.509]Chi-squared
Secondary
Percentage of Subjects Achieving Low Disease Activity
Defined as Disease Activity Score 28 (DAS28) (CRP) \< 3.2, and remaining on randomized treatment and in the study at Week 12.
Time frame: at Week 12
Population: Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm 1: Olokizumab q4w + Methotrexate | Percentage of Subjects Achieving Low Disease Activity | 55 Participants |
| Arm 2: Olokizumab q2w + Methotrexate | Percentage of Subjects Achieving Low Disease Activity | 47 Participants |
| Arm 3: Placebo q2w + Methotrexate | Percentage of Subjects Achieving Low Disease Activity | 5 Participants |
Comparison: DAS28 low disease activity (based on DAS28 \[CRP\] \<3.2) response rate at Week 12 was estimated to be 10% in the placebo group and 30% in 64 q2w OKZ treatment groups respectively, resulting in an expected difference of 20 percentage points between OKZ q2w treatment group and placebo.p-value: <0.000197.5% CI: [0.197, 0.389]Chi-squared
Comparison: DAS28 low disease activity (based on DAS28 \[CRP\] \<3.2) response rate at Week 12 was estimated to be 10% in the placebo group and 22% in 64 mg q4w OKZ treatment group respectively, resulting in an expected difference of 12 percentage points between OKZ q4w treatment group and placebo.p-value: <0.000197.5% CI: [0.251, 0.449]Chi-squared
Secondary
Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission)
Percentage of subjects with Clinical Disease Activity Index (CDAI) ≤ 2.8 (remission) and remaining on randomized treatment and in the study at Week 24
Time frame: at Week 24
Population: Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm 1: Olokizumab q4w + Methotrexate | Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission) | 11 Participants |
| Arm 2: Olokizumab q2w + Methotrexate | Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission) | 12 Participants |
| Arm 3: Placebo q2w + Methotrexate | Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission) | 0 Participants |
p-value: <0.000297.5% CI: [0.032, 0.151]Chi-squared
p-value: <0.000397.5% CI: [0.027, 0.143]Chi-squared